ClinicalTrials.gov
public full text
Public Domain
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
his study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory neurologic immune disorders. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed/refractory neurologic immune disorders.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases#896769
- Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases#1029969
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia#1293527
- Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion#303585
- A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases#1074881
Record · ID 1378657
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive